Alemtuzumab
Treatment for Multiple Sclerosis
Typical Dosage: 12mg IV daily for 5 days; then 12mg IV daily for 3 days 12 months later
Effectiveness
93%
Safety Score
30%
Clinical Trials
46
Participants
1.5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
30
DangerousModerateSafe
Treatment Details
Dosage Range
12mg IV daily for 5 days; then 12mg IV daily for 3 days 12 months later
Time to Effect
1-3 months
Treatment Duration
Two courses, then monitoring (long-term effect)
Evidence Quality
HIGHNumber Needed to Treat (NNT)
3(Treat 3 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
3(Treat 3 patients to see 1 additional serious adverse event)
Confidence Score
93%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$100,000
Monitoring:$7,000
Side Effect Mgmt:$7,500
Total Annual:$114,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$300,000/QALY
QALYs Gained
1
Outcome-Based Costs
Cost per Responder
$127,222.22
Cost per Remission
$229,000
Comparison vs Interferon Beta-1a
Cost Difference
+$49,500/year
More expensive
QALY Difference
+0.05 QALYs
Better outcomes
Dominance
No dominance
Alemtuzumab Outcomes
for Multiple Sclerosis
Efficacy Outcomes
Overall Effectiveness
+93%
Response Rate
+90%
Remission Rate
+50%
Common Side Effects
Infusion reactions
+90%
Headache
+52%
Nasopharyngitis
+39%
Autoimmune thyroid disorders
+35%
Immune thrombocytopenic purpura (ITP)
+1%
Active Clinical Trials
1 active trial recruiting for Alemtuzumab in Multiple Sclerosis
Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS)
NCT03477500ACTIVE NOT RECRUITINGPHASE3
100 participants
INTERVENTIONAL
Copenhagen, Denmark +7 more
Started: Mar 21, 2018
Completed Clinical Trials
11 completed trials for Alemtuzumab in Multiple Sclerosis
Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis
NCT03135249COMPLETEDPHASE4
9 participants
INTERVENTIONAL
Dallas, United States +1 more
Started: May 1, 2018
Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis
NCT01395316COMPLETEDPHASE4
8 participants
INTERVENTIONAL
Started: Jun 1, 2011
LEMTRADA Pregnancy Registry in Multiple Sclerosis
NCT03774914COMPLETED
42 participants
OBSERVATIONAL
New York, United States +11 more
Started: Sep 1, 2015
ADAs to Alemtuzumab
NCT06310343COMPLETED
15 participants
OBSERVATIONAL
London, United Kingdom
Started: Jul 12, 2022
Physical and Cognitive Performance During the Two First Years of Lemtrada Treatment
NCT03806387COMPLETED
17 participants
OBSERVATIONAL
Aarhus, Denmark
Started: Mar 1, 2017
An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab
NCT00930553COMPLETEDPHASE3
1.31K participants
INTERVENTIONAL
Cullman, United States +175 more
Started: Aug 1, 2009
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential
NCT02419378COMPLETEDPHASE4
15 participants
INTERVENTIONAL
Münster, Germany
Started: Jun 1, 2015
Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two
NCT00548405COMPLETEDPHASE3
840 participants
INTERVENTIONAL
Cullman, United States +190 more
Started: Oct 1, 2007
Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409
NCT02255656COMPLETEDPHASE4
1.06K participants
INTERVENTIONAL
Cullman, United States +130 more
Started: Jan 7, 2015
Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One
NCT00530348COMPLETEDPHASE3
581 participants
INTERVENTIONAL
Cullman, United States +100 more
Started: Aug 1, 2007
A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosis
NCT02583594COMPLETEDPHASE1
24 participants
INTERVENTIONAL
Barcelona, Spain
Started: Dec 6, 2015
Showing 20 of 46 total trials